T2 Biosystems Inc. buy tamam
Summary
This prediction ended on 03.12.18 with a price of €200.25. The BUY prediction by tamam for T2 Biosystems Inc. performed very badly with a performance of -45.59%. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| T2 Biosystems Inc. | - | - | - | - |
| iShares Core DAX® | -0.530% | 2.858% | 15.472% | 17.034% |
| iShares Nasdaq 100 | -0.580% | 4.871% | 28.534% | 54.277% |
| iShares Nikkei 225® | -1.097% | -1.658% | 7.461% | 3.656% |
| iShares S&P 500 | -0.730% | 2.647% | 24.918% | 45.236% |
Comments by tamam for this prediction
In the thread T2 Biosystems Inc. diskutieren
T2 is highly underpenetrated in its core markets
This week's T2bacteria FDA clearance expands the company's market opportunity "dramatically" from $1.4 billion to over $3 billion. T2 is highly underpenetrated in its core markets, but feels it can now penetrate the broader $1.5 billion-$2.0 billion bacterial sepsis market with an immediate entry into the hospital emergency departments, which the analyst values at $300 million.
This is a huge development. First, this panel will reduce the time to hours from days it currently takes to process a sample to determine if sepsis is present.
This deadly infection that takes numerous forms kills more people in the United States than prostrate cancer, AIDS and breast cancer combined yet gets little mention in the press. It is a continuing scourge made worse by the overuse of antibiotics resulting in more and more drug resistant forms of this type of infection. In trials, T2's new panel provided 90% sensitivity (correctly identifying true positives) and 98% specificity (correctly identifying true negatives)